Hospira Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HOSPIRA, and when can generic versions of HOSPIRA drugs launch?
HOSPIRA has five hundred and eighteen approved drugs.
There are nine US patents protecting HOSPIRA drugs. There are seven tentative approvals on HOSPIRA drugs.
There are sixty-nine patent family members on HOSPIRA drugs in thirty-eight countries and four hundred and nineteen supplementary protection certificates in sixteen countries.
Summary for Hospira
| International Patents: | 69 |
| US Patents: | 9 |
| Tradenames: | 333 |
| Ingredients: | 210 |
| NDAs: | 518 |
| Patent Litigation for Hospira: | See patent lawsuits for Hospira |
| PTAB Cases with Hospira as petitioner: | See PTAB cases with Hospira as petitioner |
Drugs and US Patents for Hospira
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | LORAZEPAM | lorazepam | INJECTABLE;INJECTION | 074300-001 | Apr 12, 1994 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Hospira | BUPIVACAINE HYDROCHLORIDE | bupivacaine hydrochloride | INJECTABLE;SPINAL | 071810-001 | Dec 11, 1987 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Hospira | HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | heparin sodium | INJECTABLE;INJECTION | 018916-006 | Jan 31, 1984 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Hospira | ARGATROBAN | argatroban | INJECTABLE;INJECTION | 204120-001 | Sep 21, 2016 | AP | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Hospira | LIDOCAINE HYDROCHLORIDE | lidocaine hydrochloride | INJECTABLE;INJECTION | 040078-001 | Jun 23, 1995 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hospira
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-001 | Dec 17, 1999 | 4,910,214*PED | ⤷ Try a Trial |
| Hospira | BRETYLOL | bretylium tosylate | INJECTABLE;INJECTION | 017954-001 | Approved Prior to Jan 1, 1982 | RE29618 | ⤷ Try a Trial |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-003 | Mar 13, 2013 | 6,716,867*PED | ⤷ Try a Trial |
| Hospira | TRACRIUM PRESERVATIVE FREE | atracurium besylate | INJECTABLE;INJECTION | 018831-001 | Nov 23, 1983 | 4,179,507 | ⤷ Try a Trial |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-001 | Dec 17, 1999 | 6,716,867*PED | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HOSPIRA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
| ➤ Subscribe | Injection | 4 mcg/mL, 50 mL and 100 mL vials | ➤ Subscribe | 2013-12-26 |
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
| ➤ Subscribe | Injection | 100 mcg/mL | ➤ Subscribe | 2009-04-08 |
| ➤ Subscribe | Injection | 4 mcg/mL, 20 mL vials | ➤ Subscribe | 2015-09-30 |
International Patents for Hospira Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2895187 | ⤷ Try a Trial |
| Taiwan | 201332546 | ⤷ Try a Trial |
| Hungary | E13837694 | ⤷ Try a Trial |
| Japan | 2015110639 | ⤷ Try a Trial |
| New Zealand | 742241 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hospira Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2785706 | C02785706/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: FOSNETUPITANT, PALONOSETRON.; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68290 01.09.2022 |
| 1255752 | C 2008 002 | Romania | ⤷ Try a Trial | PRODUCT NAME: N-[2-(DIETILAMINO)ETIL]-5-[(Z)-(5-FLUORO-2-OXO-1,2-DIHIDRO-3H-INDOL-3-ILIDEN)METIL]-2,4-DIMETIL-1H-PIROL-3-CAROXAMIDA - SUNITINIB, OPTIONAL SUB FORMA UNEI SARI ACCEPTABILE FARMACEUTIC,INCLUSIV A SARII L-MALAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/06/347/001, RO EU/1/06/347/002, RO EU/1/06/347/003; DATE OF NATIONAL AUTHORISATION: 20060719; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/06/347/001, EU/1/06/347/002, EU/1/06/347/003; DATE OF FIRST AUTHORISATION IN EEA: 20060719 |
| 1441735 | SPC/GB08/020 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
| 2666774 | 132020000000073 | Italy | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, OPZIONALMENTE IN FORMA DEL MONOIDRATO, IMIPENEM E CILASTATINA, OPZIONALMENTE NELLA FORMA DEL SALE SODICO(RECARBRIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1420, 20200217 |
| 2404919 | PA2016015,C2404919 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOKSOL-5-IL)CIKLOPROPANKARBONIL)AMINO)-3-METILPIRIDIN-2-IL)BENZOINE RUGSTIS ARBA JOS FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA ESTERIS; REGISTRATION NO/DATE: EU/1/15/1059 20151119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
